MAPT and Alzheimer disease: Tau phosphorylated at Threonine 181 (p-T181), t-tau and Aβ42 have been extensively validated in the CSF as biomarkers of AD and are currently widely used as diagnostic benchmarks in clinical and research studies [54,109,212].